Recall Register

Drug recall: Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension Rx Only, For Use in Ears Only, Manufactured By: Novartis…

Class II FDA enforcement event 97431. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

Temperature Abuse

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Sandoz Inc started this drug recall on 13 Aug 2025. The firm address in the FDA record is in Princeton, NJ. FDA put the recall in Class II. FDA event 97431 has 1 product record. The first FDA enforcement report date is 17 Sep 2025. The record gives the status Ongoing.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Product was distributed to one consignee in CA.

Recalling firm

Sandoz Inc, Princeton, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 97431: product records
Recall numberProductQuantityClassStatusReport date
D-0626-2025Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension Rx Only, For Use in Ears Only, Manufactured By: Novartis Manufacturing NV, Belgium, Distributed by: Sandoz, Inc., Princeton, NJ, NDC# 0781-6186-67, Carton NDC# 0781-6186-671,680 bottlesClass IIOngoing17 Sep 2025

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2025
322
Share of these events in Class II
79%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
30

Other events of the firm

Other FDA enforcement events of Sandoz Inc
InitiatedProduct (first record)TypeClassRecords
1 Jun 2026Focalin XR (dexmethylphenidate HCl) 5 mg, 30 extended-release capsules per bottle, Rx only, Manufactured by Societal CDMDrugClass III1
5 Sep 2025Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL), Hazardous Drug, Rx Only, Sterile, 5mL Multiple Dose Vial, ManufacturDrugClass II1
27 Jun 2025Cefazolin for Injection, USP, 1 gram per vial, Sterile, For Intramuscular or Intravenous Use, Rx Only, Manufactured by SDrugClass I2
21 Mar 2022Orphenadrine Citrate Extended-Release Tablets, USP 100 mg, Rx Only, 100 Tablets, Manufactured by Sandoz Inc., Princeton,DrugClass II1
17 Nov 2021Enoxaparin Sodium Injection, USP, 40 mg/0.4 mL, Single-Dose Syringes with Automatic Safety Device, For Subcutaneous InjeDrugClass I1
21 Apr 2020Infuvite PEDiatric Pharmacy, kit in 1 carton (40 mL fill in a 50 mL) vial 1 and (10 mL) in vial 2, Rx Only, Distributed DrugClass II1
17 Oct 2019Bimatoprost Ophthalmic Solution 0.03%, Rx Only, For Topical Application to the Upper Eyelid, Sterile, a) 3 mL bottle NDCDrugClass III3
23 Sep 2019Sandoz Ranitidine Hydrochloride Capsules 150mg 60 Capsules Rx Only Manufactured by Sandoz Inc. Princeton, NJ Product of DrugClass II3
2 Nov 2018Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, packaged in a) 100-capsule bottles (NDC 0185-0122-01); DrugClass II6
1 Nov 2018Sandoz Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg, 1000-count bottles, Rx Only, Finished Drug DrugClass II1

Sandoz Inc: all 30 events

Official channels

Cite this page

Recall Register. FDA enforcement event 97431. https://recallregister.com/fda/ii/97431/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Product was distributed to one consignee in CA.
What quantity of product is in FDA event 97431?
The FDA record gives this quantity: 1,680 bottles
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2025 have the same class?
79% of the 322 drug events that started in 2025 are in Class II.